China's BCI Companies Move From Lab to Market as First Invasive Device Wins Approval

From Lab to Clinic: How China's BCI Industry Is Moving to Commercial Use

Brain-computer interface companies in China are entering their first real commercialization year, industry executives said at a Yicai forum. The shift from lab demonstrations to clinical reality was underscored by Neuracle Technology Shanghai's NEO implantable BCI, which on March 13 became the world's first invasive BCI to win Class III medical device registration. On July 13, the device was prescribed commercially for the first time at Huashan Hospital, where the first post-approval implant surgery was also completed. The same hospital began a state-mandated Good Clinical Practice registration trial for NeuroXess's fully implantable, wireless BCI system on July 7, and both developments signal that 2026 is a turning point.

Beyond the regulatory milestone, companies are revealing distinct commercial paths. NeuroXess's assistant president Zhang Zichao said its fully implantable system has been applied to brain-controlled exoskeleton gloves, smart wheelchairs and robots, reaching an information transfer rate of 5.2 bits per second in fully brain-controlled mode. The firm achieved full-spectrum Chinese speech decoding last year, though commercialization of that pathway lags motor applications. StairMed, which raised CNY500 million (USD70 million) in March and has raised more than CNY2 billion to date, will focus on motor/speech disorders and psychiatric conditions for the next three to five years before expanding to consumer applications. Non-invasive approaches are also advancing: Sunnyou Medical, listed in Shanghai, has built ten BCI-enabled rehabilitation pathways covering stroke, Parkinson's disease and childhood attention disorders. Early-stage firm JN Medtech is avoiding the hand-motor path validated by leaders, targeting more vertical clinical indications in close collaboration with neurosurgeons.

Detong Capital partner Yu Jiani, who has followed Neuracle's path to approval, stressed that regulatory clearance is only the first step. Companies must now manage production capacity and costs — NeuroXess has begun building a mass-production facility targeting tens of thousands of units annually — while driving clinical adoption among doctors who remain largely unfamiliar with the technology. An implant is "invisible and intangible," she noted; the real value must be shown through the exoskeletons, wheelchairs, robots and large language models it connects to. Payment is equally critical: the first commercial NEO prescription was partly covered by Shanghai's Huhuibao supplementary insurance program, and BCI has been included in the reference scope for the fifth set of listing standards on the Shanghai Star Market, EY executive Tang Zhehui pointed out, suggesting that inclusion in national medical insurance could further expand the addressable market.

Despite the progress, the industry's own benchmarks underline how slowly adoption may come. Yu pointed to deep brain stimulation technology, which after more than two decades in China is used in only about 16,000 clinical cases per year. "Any new tech takes time to go from rollout to maturity," she said. "Only once we see more real-world efficacy and safety data will it be able to spread more widely."

Behind the Shift: Differentiated Strategies and Real-World Hurdles

The Neuracle Milestone: Proving the Regulatory Path

The world-first Class III approval for an invasive BCI is a concrete validation that Chinese firms have moved ahead of Western counterparts in commercial readiness for an implantable neural device. However, the NEO device is specifically for hand motor compensation in a defined patient group, so the regulatory precedent applies only to that narrow indication. The real test will be whether subsequent devices — such as NeuroXess's system now in GCP trials — can replicate the approval for speech or visual decoding. Even within motor applications, scaling to broader use will require building registries of safety and efficacy data that satisfy both regulators and skeptical clinicians.

Implantable vs. Non-Invasive: Distinct Business Models

The strategies now forming reveal two very different bets. Neuracle and NeuroXess are pursuing fully implantable systems, treating platform-level engineering — spanning electrodes, chips, batteries and software — as their core moat. StairMed's Assistant General Manager Chen Yaoxu described a system that can support different application scenarios, essentially a hardware-software platform that can be rolled out across motor, speech and eventually psychiatric conditions. In contrast, Sunnyou Medical is leveraging non-invasive BCI to upgrade rehabilitation care, turning passive training into closed-loop active participation for stroke and Alzheimer's patients. JN Medtech is carving an even narrower path by avoiding validated hand-motor rehab entirely and focusing on niche clinical indications where deep collaboration with neurosurgeons can define product specifications. This divergence suggests that no single technology will dominate the entire BCI landscape, but it also raises questions about how many commercial models the healthcare system can sustainably support.

The Hurdles Beyond Approval: Production, Payment and Clinician Trust

Yu Jiani's checklist of post-approval challenges is revealing. Building a mass-production line for an invasive neural implant is not a trivial semiconductor scaling exercise; it requires strict control over biocompatibility, surgical reliability and cost, especially if the device is to be reimbursed through insurance. The fact that NeuroXess is already investing in a facility signals that the path from clinical trial batch to thousands of units is being taken seriously. Payment mechanisms remain fragile: the Huhuibao supplementary insurance is a limited, regional solution, and meaningful national reimbursement would require evidence of long-term health-economic benefit that simply doesn't exist yet. Clinician adoption may prove the toughest barrier. Most neurosurgeons have no experience with BCI systems, and as Yu said, an implant by itself is "invisible and intangible" — its utility depends on an ecosystem of connected devices that is still being assembled.

Investor Sentiment and the Long Road to Adoption

While StairMed's large funding round shows that capital is flowing, seasoned voices urge caution. Yu's reference to DBS's two-decade journey to just 16,000 annual cases in China is a sobering benchmark for BCI's likely trajectory. The Star Market listing possibility may attract more investment in the near term, but Tang's comments suggest that inclusion in a listing standard is aspirational, not guaranteed. Investors who chase the approval headlines risk overestimating the speed of commercial uptake. Real value will accrue to companies that not only secure regulatory nods but also build the clinician training programs, reimbursement evidence and manufacturing reliability that turn an experimental implant into a standard-of-care product.

What the Commercial Ramp-Up Means for BCI Companies, Investors and Clinicians

• For BCI developers: Beyond regulatory approval, prioritize building clinician training programs and demonstrating safety/efficacy data in real-world settings. Neuracle's first commercial prescription and NeuroXess's GCP trial show that early adopter hospitals are crucial partners; replicating that will require dedicated resources to make the technology understandable to surgeons, not just engineers.
• For investors and acquirers: Scrutinize companies' plans to bridge the production gap (e.g., NeuroXess's planned facility) and their ability to secure permanent reimbursement pathways. The DBS case — 20 years to 16,000 annual cases — suggests that BCI adoption will be measured in decades, not quarters. Homogeneous R&D is a recognized risk; back teams that have a clear, differentiated clinical focus and a strategy for integrating with exoskeletons, wheelchairs, robots and software, as Yu Jiani emphasized.
• For hospitals and clinicians: Prepare for the arrival of implantable BCI by evaluating how these devices connect to existing rehabilitation and assistive technologies. The value of the implant is realized only through its ecosystem; early engagement with companies during GCP trials can shape how these systems are integrated into patient pathways and may influence future reimbursement decisions.
• For regulators and payers: Monitor the real-world evidence that will emerge from the NEO post-market experience and from upcoming trials. The inclusion of BCI in the Star Market listing reference scope and the Huhuibao coverage pilot signal willingness to support the sector, but any expansion of national insurance will depend on demonstrable cost-effectiveness and safety profiles that are still being built.